Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer
Background Wax microsphere bound oxycodone was developed as an abuse-deterrent opioid and maintains a similar pharmacokinetic profile whether administered with or without an intact capsule. We hypothesized that microsphere oxycodone could be utilized for extended release analgesia in patients underg...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2021, Vol.29 (1), p.263-269 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 269 |
|---|---|
| container_issue | 1 |
| container_start_page | 263 |
| container_title | Supportive care in cancer |
| container_volume | 29 |
| creator | McDonald, Andrew M. Spencer, Sharon A. Willey, Christopher D. Bonner, James A. Dobelbower, Michael C. Swain, Thomas A. Nabell, Lisle McCammon, Susan Carroll, William R. McGwin, Gerald Bhatia, Smita Yang, Eddy S. |
| description | Background
Wax microsphere bound oxycodone was developed as an abuse-deterrent opioid and maintains a similar pharmacokinetic profile whether administered with or without an intact capsule. We hypothesized that microsphere oxycodone could be utilized for extended release analgesia in patients undergoing radiation (RT) for head-and-neck cancer (HNC) and would not need to be discontinued due to dysphagia or gastrostomy tube dependence.
Methods and materials
We performed a prospective trial that enrolled participants > 18 years with histologically confirmed HNC who were scheduled to receive RT. Analgesia was prescribed in accordance with the WHO pain ladder. Microsphere oxycodone was initiated when total daily opioid dose exceeded 30 mg of morphine sulfate equivalent and was titrated weekly during RT. Pain level and effect on quality of life were assessed using the Brief Pain Inventory. The primary feasibility endpoint was frequency of microsphere oxycodone discontinuation within 3 months of RT for reasons other than pain resolution.
Results
Twenty-six eligible patients were enrolled. Microsphere oxycodone was initiated in 16 (61.5%) patients. Six (23.1%) patients utilized a gastrostomy tube to administer microsphere oxycodone during all or part of RT. Microsphere oxycodone was discontinued in 1 (7.6%) patient due to perceived inefficacy. No patients were discontinued due to toxicity or difficulty with administration. Ratings for average pain was 3.1 (± 3.4) at enrollment, 4.0 (± 2.4) at week 6 of RT, and 1.8 (± 2.2) at 3-month follow-up.
Conclusions
These results support the feasibility and safety of microsphere oxycodone for extended release analgesia among patients with HNC undergoing RT. |
| doi_str_mv | 10.1007/s00520-020-05474-1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2473345681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A650996200</galeid><sourcerecordid>A650996200</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-b5f9c2079882b9e5dae35e973941ba0d825d5ba90b535ae730e8c1d2535895753</originalsourceid><addsrcrecordid>eNp9UU2PFCEQJUbjjqt_wIMh8dxr8TU0x83GVZNJvOiZ0FA9y7oNvdBjnH8v7axuTIwhFSh471H1ipDXDC4YgH5XARSHDtZQUsuOPSEbJoXotBDmKdmAkayTQqkz8qLWWwCmteLPyZngQsFWw4bc7-IcA52iL7nON1iQDvmQAs0_jj6HnJCOudDZxUQnl9weJ0wLbdnsltiOlRb0GL_HtKfFhZiXJuLm4y_aDbpAXVNL6L9R75LH8pI8G91dxVcP-zn5ev3-y9XHbvf5w6ery13npeRLN6jReA7a9D0fDKrgUCg0WrSeBgeh5yqowRkYlFAOtQDsPQu8Zb1RWolz8vakO5d8f8C62Nt8KKl9ablsBkm17dkjau_u0MY05qU4P8Xq7eVWgTFbDtBQF_9AtRWwOddMGmO7_4vAT4TV1lpwtHOJkytHy8Cuw7On4VlYYx2eXWt581DxYZgw_KH8nlYDiBOgtqe0x_LY0n9kfwJTVKOk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473345681</pqid></control><display><type>article</type><title>Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>McDonald, Andrew M. ; Spencer, Sharon A. ; Willey, Christopher D. ; Bonner, James A. ; Dobelbower, Michael C. ; Swain, Thomas A. ; Nabell, Lisle ; McCammon, Susan ; Carroll, William R. ; McGwin, Gerald ; Bhatia, Smita ; Yang, Eddy S.</creator><creatorcontrib>McDonald, Andrew M. ; Spencer, Sharon A. ; Willey, Christopher D. ; Bonner, James A. ; Dobelbower, Michael C. ; Swain, Thomas A. ; Nabell, Lisle ; McCammon, Susan ; Carroll, William R. ; McGwin, Gerald ; Bhatia, Smita ; Yang, Eddy S.</creatorcontrib><description>Background
Wax microsphere bound oxycodone was developed as an abuse-deterrent opioid and maintains a similar pharmacokinetic profile whether administered with or without an intact capsule. We hypothesized that microsphere oxycodone could be utilized for extended release analgesia in patients undergoing radiation (RT) for head-and-neck cancer (HNC) and would not need to be discontinued due to dysphagia or gastrostomy tube dependence.
Methods and materials
We performed a prospective trial that enrolled participants > 18 years with histologically confirmed HNC who were scheduled to receive RT. Analgesia was prescribed in accordance with the WHO pain ladder. Microsphere oxycodone was initiated when total daily opioid dose exceeded 30 mg of morphine sulfate equivalent and was titrated weekly during RT. Pain level and effect on quality of life were assessed using the Brief Pain Inventory. The primary feasibility endpoint was frequency of microsphere oxycodone discontinuation within 3 months of RT for reasons other than pain resolution.
Results
Twenty-six eligible patients were enrolled. Microsphere oxycodone was initiated in 16 (61.5%) patients. Six (23.1%) patients utilized a gastrostomy tube to administer microsphere oxycodone during all or part of RT. Microsphere oxycodone was discontinued in 1 (7.6%) patient due to perceived inefficacy. No patients were discontinued due to toxicity or difficulty with administration. Ratings for average pain was 3.1 (± 3.4) at enrollment, 4.0 (± 2.4) at week 6 of RT, and 1.8 (± 2.2) at 3-month follow-up.
Conclusions
These results support the feasibility and safety of microsphere oxycodone for extended release analgesia among patients with HNC undergoing RT.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-020-05474-1</identifier><identifier>PMID: 32350670</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Analgesia ; Analgesics, Opioid - therapeutic use ; Cancer ; Care and treatment ; Central nervous system depressants ; Deglutition Disorders ; Delayed-Action Preparations - therapeutic use ; Female ; Gastrostomy ; Head & neck cancer ; Head and Neck Neoplasms - radiotherapy ; Humans ; Male ; Medicine ; Medicine & Public Health ; Microspheres ; Middle Aged ; Morphine ; Morphine - therapeutic use ; Mucositis - prevention & control ; Narcotics ; Nursing ; Nursing Research ; Oncology ; Opioid-Related Disorders - prevention & control ; Original Article ; Ostomy ; Oxycodone - administration & dosage ; Oxycodone - therapeutic use ; Pain ; Pain - drug therapy ; Pain management ; Pain Management - methods ; Pain Medicine ; Prospective Studies ; Quality of Life - psychology ; Radiation therapy ; Radiotherapy ; Rehabilitation Medicine ; Sulfates</subject><ispartof>Supportive care in cancer, 2021, Vol.29 (1), p.263-269</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>COPYRIGHT 2021 Springer</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-b5f9c2079882b9e5dae35e973941ba0d825d5ba90b535ae730e8c1d2535895753</citedby><cites>FETCH-LOGICAL-c442t-b5f9c2079882b9e5dae35e973941ba0d825d5ba90b535ae730e8c1d2535895753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-020-05474-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-020-05474-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32350670$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McDonald, Andrew M.</creatorcontrib><creatorcontrib>Spencer, Sharon A.</creatorcontrib><creatorcontrib>Willey, Christopher D.</creatorcontrib><creatorcontrib>Bonner, James A.</creatorcontrib><creatorcontrib>Dobelbower, Michael C.</creatorcontrib><creatorcontrib>Swain, Thomas A.</creatorcontrib><creatorcontrib>Nabell, Lisle</creatorcontrib><creatorcontrib>McCammon, Susan</creatorcontrib><creatorcontrib>Carroll, William R.</creatorcontrib><creatorcontrib>McGwin, Gerald</creatorcontrib><creatorcontrib>Bhatia, Smita</creatorcontrib><creatorcontrib>Yang, Eddy S.</creatorcontrib><title>Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Background
Wax microsphere bound oxycodone was developed as an abuse-deterrent opioid and maintains a similar pharmacokinetic profile whether administered with or without an intact capsule. We hypothesized that microsphere oxycodone could be utilized for extended release analgesia in patients undergoing radiation (RT) for head-and-neck cancer (HNC) and would not need to be discontinued due to dysphagia or gastrostomy tube dependence.
Methods and materials
We performed a prospective trial that enrolled participants > 18 years with histologically confirmed HNC who were scheduled to receive RT. Analgesia was prescribed in accordance with the WHO pain ladder. Microsphere oxycodone was initiated when total daily opioid dose exceeded 30 mg of morphine sulfate equivalent and was titrated weekly during RT. Pain level and effect on quality of life were assessed using the Brief Pain Inventory. The primary feasibility endpoint was frequency of microsphere oxycodone discontinuation within 3 months of RT for reasons other than pain resolution.
Results
Twenty-six eligible patients were enrolled. Microsphere oxycodone was initiated in 16 (61.5%) patients. Six (23.1%) patients utilized a gastrostomy tube to administer microsphere oxycodone during all or part of RT. Microsphere oxycodone was discontinued in 1 (7.6%) patient due to perceived inefficacy. No patients were discontinued due to toxicity or difficulty with administration. Ratings for average pain was 3.1 (± 3.4) at enrollment, 4.0 (± 2.4) at week 6 of RT, and 1.8 (± 2.2) at 3-month follow-up.
Conclusions
These results support the feasibility and safety of microsphere oxycodone for extended release analgesia among patients with HNC undergoing RT.</description><subject>Analgesia</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Central nervous system depressants</subject><subject>Deglutition Disorders</subject><subject>Delayed-Action Preparations - therapeutic use</subject><subject>Female</subject><subject>Gastrostomy</subject><subject>Head & neck cancer</subject><subject>Head and Neck Neoplasms - radiotherapy</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Microspheres</subject><subject>Middle Aged</subject><subject>Morphine</subject><subject>Morphine - therapeutic use</subject><subject>Mucositis - prevention & control</subject><subject>Narcotics</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Opioid-Related Disorders - prevention & control</subject><subject>Original Article</subject><subject>Ostomy</subject><subject>Oxycodone - administration & dosage</subject><subject>Oxycodone - therapeutic use</subject><subject>Pain</subject><subject>Pain - drug therapy</subject><subject>Pain management</subject><subject>Pain Management - methods</subject><subject>Pain Medicine</subject><subject>Prospective Studies</subject><subject>Quality of Life - psychology</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Rehabilitation Medicine</subject><subject>Sulfates</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9UU2PFCEQJUbjjqt_wIMh8dxr8TU0x83GVZNJvOiZ0FA9y7oNvdBjnH8v7axuTIwhFSh471H1ipDXDC4YgH5XARSHDtZQUsuOPSEbJoXotBDmKdmAkayTQqkz8qLWWwCmteLPyZngQsFWw4bc7-IcA52iL7nON1iQDvmQAs0_jj6HnJCOudDZxUQnl9weJ0wLbdnsltiOlRb0GL_HtKfFhZiXJuLm4y_aDbpAXVNL6L9R75LH8pI8G91dxVcP-zn5ev3-y9XHbvf5w6ery13npeRLN6jReA7a9D0fDKrgUCg0WrSeBgeh5yqowRkYlFAOtQDsPQu8Zb1RWolz8vakO5d8f8C62Nt8KKl9ablsBkm17dkjau_u0MY05qU4P8Xq7eVWgTFbDtBQF_9AtRWwOddMGmO7_4vAT4TV1lpwtHOJkytHy8Cuw7On4VlYYx2eXWt581DxYZgw_KH8nlYDiBOgtqe0x_LY0n9kfwJTVKOk</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>McDonald, Andrew M.</creator><creator>Spencer, Sharon A.</creator><creator>Willey, Christopher D.</creator><creator>Bonner, James A.</creator><creator>Dobelbower, Michael C.</creator><creator>Swain, Thomas A.</creator><creator>Nabell, Lisle</creator><creator>McCammon, Susan</creator><creator>Carroll, William R.</creator><creator>McGwin, Gerald</creator><creator>Bhatia, Smita</creator><creator>Yang, Eddy S.</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>2021</creationdate><title>Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer</title><author>McDonald, Andrew M. ; Spencer, Sharon A. ; Willey, Christopher D. ; Bonner, James A. ; Dobelbower, Michael C. ; Swain, Thomas A. ; Nabell, Lisle ; McCammon, Susan ; Carroll, William R. ; McGwin, Gerald ; Bhatia, Smita ; Yang, Eddy S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-b5f9c2079882b9e5dae35e973941ba0d825d5ba90b535ae730e8c1d2535895753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analgesia</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Central nervous system depressants</topic><topic>Deglutition Disorders</topic><topic>Delayed-Action Preparations - therapeutic use</topic><topic>Female</topic><topic>Gastrostomy</topic><topic>Head & neck cancer</topic><topic>Head and Neck Neoplasms - radiotherapy</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Microspheres</topic><topic>Middle Aged</topic><topic>Morphine</topic><topic>Morphine - therapeutic use</topic><topic>Mucositis - prevention & control</topic><topic>Narcotics</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Opioid-Related Disorders - prevention & control</topic><topic>Original Article</topic><topic>Ostomy</topic><topic>Oxycodone - administration & dosage</topic><topic>Oxycodone - therapeutic use</topic><topic>Pain</topic><topic>Pain - drug therapy</topic><topic>Pain management</topic><topic>Pain Management - methods</topic><topic>Pain Medicine</topic><topic>Prospective Studies</topic><topic>Quality of Life - psychology</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Rehabilitation Medicine</topic><topic>Sulfates</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McDonald, Andrew M.</creatorcontrib><creatorcontrib>Spencer, Sharon A.</creatorcontrib><creatorcontrib>Willey, Christopher D.</creatorcontrib><creatorcontrib>Bonner, James A.</creatorcontrib><creatorcontrib>Dobelbower, Michael C.</creatorcontrib><creatorcontrib>Swain, Thomas A.</creatorcontrib><creatorcontrib>Nabell, Lisle</creatorcontrib><creatorcontrib>McCammon, Susan</creatorcontrib><creatorcontrib>Carroll, William R.</creatorcontrib><creatorcontrib>McGwin, Gerald</creatorcontrib><creatorcontrib>Bhatia, Smita</creatorcontrib><creatorcontrib>Yang, Eddy S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McDonald, Andrew M.</au><au>Spencer, Sharon A.</au><au>Willey, Christopher D.</au><au>Bonner, James A.</au><au>Dobelbower, Michael C.</au><au>Swain, Thomas A.</au><au>Nabell, Lisle</au><au>McCammon, Susan</au><au>Carroll, William R.</au><au>McGwin, Gerald</au><au>Bhatia, Smita</au><au>Yang, Eddy S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2021</date><risdate>2021</risdate><volume>29</volume><issue>1</issue><spage>263</spage><epage>269</epage><pages>263-269</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Background
Wax microsphere bound oxycodone was developed as an abuse-deterrent opioid and maintains a similar pharmacokinetic profile whether administered with or without an intact capsule. We hypothesized that microsphere oxycodone could be utilized for extended release analgesia in patients undergoing radiation (RT) for head-and-neck cancer (HNC) and would not need to be discontinued due to dysphagia or gastrostomy tube dependence.
Methods and materials
We performed a prospective trial that enrolled participants > 18 years with histologically confirmed HNC who were scheduled to receive RT. Analgesia was prescribed in accordance with the WHO pain ladder. Microsphere oxycodone was initiated when total daily opioid dose exceeded 30 mg of morphine sulfate equivalent and was titrated weekly during RT. Pain level and effect on quality of life were assessed using the Brief Pain Inventory. The primary feasibility endpoint was frequency of microsphere oxycodone discontinuation within 3 months of RT for reasons other than pain resolution.
Results
Twenty-six eligible patients were enrolled. Microsphere oxycodone was initiated in 16 (61.5%) patients. Six (23.1%) patients utilized a gastrostomy tube to administer microsphere oxycodone during all or part of RT. Microsphere oxycodone was discontinued in 1 (7.6%) patient due to perceived inefficacy. No patients were discontinued due to toxicity or difficulty with administration. Ratings for average pain was 3.1 (± 3.4) at enrollment, 4.0 (± 2.4) at week 6 of RT, and 1.8 (± 2.2) at 3-month follow-up.
Conclusions
These results support the feasibility and safety of microsphere oxycodone for extended release analgesia among patients with HNC undergoing RT.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32350670</pmid><doi>10.1007/s00520-020-05474-1</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2021, Vol.29 (1), p.263-269 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_proquest_journals_2473345681 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Analgesia Analgesics, Opioid - therapeutic use Cancer Care and treatment Central nervous system depressants Deglutition Disorders Delayed-Action Preparations - therapeutic use Female Gastrostomy Head & neck cancer Head and Neck Neoplasms - radiotherapy Humans Male Medicine Medicine & Public Health Microspheres Middle Aged Morphine Morphine - therapeutic use Mucositis - prevention & control Narcotics Nursing Nursing Research Oncology Opioid-Related Disorders - prevention & control Original Article Ostomy Oxycodone - administration & dosage Oxycodone - therapeutic use Pain Pain - drug therapy Pain management Pain Management - methods Pain Medicine Prospective Studies Quality of Life - psychology Radiation therapy Radiotherapy Rehabilitation Medicine Sulfates |
| title | Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T08%3A52%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20microsphere%20bound%20oxycodone%20for%20pain%20management%20in%20patients%20receiving%20radiotherapy%20for%20head%20and%20neck%20cancer&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=McDonald,%20Andrew%20M.&rft.date=2021&rft.volume=29&rft.issue=1&rft.spage=263&rft.epage=269&rft.pages=263-269&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-020-05474-1&rft_dat=%3Cgale_proqu%3EA650996200%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473345681&rft_id=info:pmid/32350670&rft_galeid=A650996200&rfr_iscdi=true |